Eisai in deal to acquire MGI Pharma for $3.9 billion

Share this article:

Japanese drugmaker Eisai said Monday it would pay $3.9 billion in cash to buy Bloomington, MN,-based MGI Pharma.

The deal marks the largest acquisition of a foreign firm of any kind by a Japanese company so far this year, according to data tracker Thomson Financial.

Faced with major patent expiries in the US, Eisai is seeking to boost its product line.

Eisai's Aricept for Alzheimer's, which had sales of around $800 million in 2006, will lose patent protection in 2010, and has left the company looking for other drugs to fill the hole.
 
MGI Pharma makes Aloxi, an injection for cancer patients to help prevent post-chemotherapy nausea and vomiting. It also sells injectable Dacogen for the treatment of bone marrow disease myelodysplastic syndrome, the Gliadel Wafer for brain cancer, and Hexalen, a chemotherapy treatment for ovarian cancer. MGI Pharma reported 2006 sales of $342.8 million.

Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.